About SPIROCOR™ Ltd.

SPIROCOR™ Ltd., headquartered in Israel, has developed a proprietary non-invasive platform to facilitate physicians’ diagnosis of Significant Coronary Artery Disease (S-CAD). The SPIROCOR™ diagnostic test is a fast and simple test. It features:

• 90 second performance time
• radiation free
• no contrast agent
• no treadmill
• no adenosine
• suitable for office setting

Results of three clinical studies have been presented at scientific meetings. These results consistently showed that the SPIROCOR™ test detects S-CAD and correlates well with diagnostic angiography.